Commentary

iMedPub Journals
www.imedpub.com

Journal of Applied Microbiology and Biochemistry
ISSN 2576-1412

2024
Vol.8 No. 5:244

CRISPR-Cas9 and the Next Generation of Cancer Immunotherapy

Lily Winters*

Department of Microbial Science, University of California, Berkeley, United States of America

Corresponding author: Lily Winters, Department of Microbial Science, University of California, Berkeley, United States of America, E-mail: lilywinters10@gmail.com

Received date: September 20, 2024, Manuscript No. IPJAMB-24-19866; **Editor assigned date:** September 23,2024, PreQC No. IPJAMB-24-19866 (PQ); **Reviewed date:** October 07, 2024, QC No. IPJAMB-24-19866; **Revised date:** October 14, 2024, Manuscript No. IPJAMB-24-19866 (R); **Published date:** October 21, 2024 DOI: 10.36648/2576-1412.8.5.244

Citation: Winters L (2024) CRISPR-Cas9 and the Next Generation of Cancer Immunotherapy. J Appl Microbiol Biochem Vol. 8 No.5:244.

Description

Cancer remains one of the leading causes of death worldwide, with new cases rising annually despite advancements in treatment. While conventional approaches like chemotherapy, surgery, and radiation have long been staples of cancer care, they often come with severe side effects and varying levels of efficacy, particularly in advanced or resistant cases. One emerging alternative is immunotherapy, which leverages the body's immune system to target and eliminate cancer cells. Among the latest innovations in this field is Clustered Regularly Interspaced Short Palindromic Repeats-Cas9, a gene-editing tool that enables scientists to alter DNA with remarkable precision. By enhancing immune cells with CRISPR-Cas9, researchers are developing more potent and tailored cancer immunotherapies, sparking hope for new, effective treatment options.

CRISPR-Cas9 and evolution of immunotherapy

CRISPR-Cas9, often described as "molecular scissors," allows scientists to precisely edit specific genes, changing how cells behave. This targeted approach enables researchers to delete, insert, or modify genes, which has deep implications for treating genetically driven diseases like cancer. When paired with immunotherapy, CRISPR-Cas9 can transform how immune cells interact with cancer cells. One of the most successful applications of CRISPR-Cas9 in immunotherapy is Chimeric Antigen Receptor T-cell (CAR-T) therapy. CAR-T therapy involves extracting a patient's T cells, modifying them in the lab to better recognize cancer cells and then reinfusing them back into the patient. Traditionally, CAR-T cells are engineered using viral vectors, but CRISPR-Cas9 offers a more precise and cost-effective alternative. By editing the genes of these T cells directly, CRISPR-Cas9 enables scientists to enhance their cancer-fighting abilities with fewer risks. For example, CRISPR can be used to knock out genes that regulate the immune response, creating T cells that are better equipped to recognize and attack cancer cells without being suppressed by the body's regulatory mechanisms. By editing cells from healthy donors, scientists can create universal CAR-T cells that do not need to be patient-specific. CRISPR helps remove genes that would cause the donor's cells to be rejected, making it feasible to use these modified cells in a wider range of patients. This innovation could make CAR-T therapy more accessible and reduce the time needed to develop treatments, which is especially important for patients with aggressive cancers.

Targeting PD-1 to amplify immune response

The immune checkpoint protein PD-1, which stands for programmed cell death protein-1, is a significant focus in immunotherapy research. PD-1 acts as a "brake" on immune cells, limiting their activity to prevent an overreaction that could harm the body's tissues. However, many cancer cells exploit this pathway by expressing PD-L1, a ligand that binds to PD-1, effectively suppressing the immune response and allowing the tumour to evade detection. CRISPR-Cas9 offers a way to combat this immune evasion strategy by knocking out the PD-1 gene in T cells, effectively disabling this checkpoint and enabling T cells to mount a stronger attack against cancer cells. PD-1 knockout T cells are thus more resilient, capable of bypassing the immune-suppressive signals from cancer cells. Clinical trials using CRISPR-edited T cells are underway, analyze the efficacy and safety of this approach in cancers that have traditionally resisted standard therapies. The use of CRISPR to alter PD-1 pathways in immune cells offers a twofold benefit. First, it amplifies the immune system's ability to recognize and attack tumours. Second, this approach targets cancers that don't typically respond well to existing checkpoint inhibitors, potentially broadening the reach of immunotherapy to a wider range of cancers. Early trials in patients with solid tumours, for instance, are showing assurance, suggesting that PD-1 editing could be transformative for those who previously had limited treatment options. CRISPR-Cas9, a bacterial protein, has the potential to revolutionize immunotherapy by creating highly targeted and resilient immune cells. However, it also poses challenges, including the risk of off-target effects, where unintended sections of the genome are edited and the potential immune system's response to the CRISPR-Cas9 machinery. Researchers are developing high-fidelity versions of CRISPR-Cas9 to improve precision and reduce the likelihood of these errors. Advances in screening technologies are also helping researchers understand and mitigate these risks, ensuring the benefits of CRISPR-based immunotherapies outweigh potential downsides. Ethical considerations are also raised, as the potential for misuse in non-therapeutic gene editing remains a concern. Regulatory oversight is essential to prevent the inappropriate application of CRISPR, particularly regarding inheritable genetic changes.

However, CRISPR edits are somatic, reducing ethical concerns associated with germline editing. CRISPR-Cas9's impact on cancer treatment is expected to grow as precision improves and techniques refine. Researchers are exploring ways to combine CRISPR with other therapies, such as radiation and chemo-therapy, to create multi-pronged approaches that improve survival rates for patients with aggressive cancers. As CRISPR applications expand to other immune cells, such as Natural Killer (NK) cells, more versatile treatments may emerge. In conclusion, CRISPR-Cas9 is driving a new era in cancer immunotherapy, providing powerful tools for creating highly targeted and resilient immune cells. As technology evolves, CRISPR-Cas9 could redefine cancer care, bringing hope to millions of patients and transforming the fight against this complex disease.